<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047671</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH062531</org_study_id>
    <secondary_id>EVA-00183-02</secondary_id>
    <secondary_id>DATR A5-ETMA</secondary_id>
    <nct_id>NCT00047671</nct_id>
  </id_info>
  <brief_title>Ethnic Variations in Antidepressant Response</brief_title>
  <official_title>Ethnic Variations in Antidepressant Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health (NIMH)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 11-week study aims to determine how genetic factors affect the way African Americans and
      Caucasians with major depression respond to antidepressant medication [citalopram (CelexaÂ®)].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depressed patients vary substantially in their responses to antidepressants. Genetic factors
      may account for a large part of these differences in response. This study will include both
      African Americans and Caucasians to examine the role of genetic factors in treatment
      response.

      Participants receive citalopram (Celexa) for 8 weeks and a placebo for 1 week. Visits occur
      once a week for 11 weeks. A variety of interviews, scales, tests, and questionnaires are used
      to assess participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>Measured weekly for 11 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects receive an FDA approved dose of Citalopram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>PDA Approved antidepressant</description>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for Major Depression

          -  African-American or Caucasian ethnic background (both parents and 3 out of 4
             grandparents)

        Exclusion Criteria:

          -  Schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal
             disorder, psychotic depression, or bipolar disorder

          -  Current drug abuse or history of drug abuse within the past 6 months

          -  Unstable medical or neurological conditions that interfere with the treatment of
             depression

          -  Allergy to citalopram

          -  Failure to respond to adequate citalopram drug trial (40 mg for at least 6 weeks)

          -  Seizure disorder

          -  Pregnancy

          -  Psychotropic medications, including antidepressants and neuroleptics

          -  Suicidal ideation or other safety issues

          -  Fluoxetine (Prozac) or MAOIs (Nardil, Parnate) in the last 2 months

          -  Ongoing cognitive behavioral therapy or intensive psychotherapy. General talk therapy
             is acceptable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA/King-Drew</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2002</study_first_submitted>
  <study_first_submitted_qc>October 15, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2002</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lisa Glassman</name_title>
    <organization>Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit</organization>
  </responsible_party>
  <keyword>Depressive Disorder</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 30, 2013</submitted>
    <returned>December 23, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

